OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
CGRP, Amylin, Immunology, and Headache Medicine
Frederick R. Taylor
Headache The Journal of Head and Face Pain (2018) Vol. 59, Iss. 1, pp. 131-150
Open Access | Times Cited: 27
Frederick R. Taylor
Headache The Journal of Head and Face Pain (2018) Vol. 59, Iss. 1, pp. 131-150
Open Access | Times Cited: 27
Showing 1-25 of 27 citing articles:
Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions
Linda Al‐Hassany, Peter J. Goadsby, A.H. Jan Danser, et al.
The Lancet Neurology (2022) Vol. 21, Iss. 3, pp. 284-294
Closed Access | Times Cited: 99
Linda Al‐Hassany, Peter J. Goadsby, A.H. Jan Danser, et al.
The Lancet Neurology (2022) Vol. 21, Iss. 3, pp. 284-294
Closed Access | Times Cited: 99
Targeting CGRP for the Prevention of Migraine and Cluster Headache: A Narrative Review
Hsiangkuo Yuan, Nicole Spare, Stephen D. Silberstein
Headache The Journal of Head and Face Pain (2019) Vol. 59, Iss. S2, pp. 20-32
Closed Access | Times Cited: 86
Hsiangkuo Yuan, Nicole Spare, Stephen D. Silberstein
Headache The Journal of Head and Face Pain (2019) Vol. 59, Iss. S2, pp. 20-32
Closed Access | Times Cited: 86
New Trends in Migraine Pharmacology: Targeting Calcitonin Gene–Related Peptide (CGRP) With Monoclonal Antibodies
Damiana Scuteri, Annagrazia Adornetto, Laura Rombolà, et al.
Frontiers in Pharmacology (2019) Vol. 10
Open Access | Times Cited: 70
Damiana Scuteri, Annagrazia Adornetto, Laura Rombolà, et al.
Frontiers in Pharmacology (2019) Vol. 10
Open Access | Times Cited: 70
Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention
Jean Schoenen, Maïté Manise, Romain Nonis, et al.
Revue Neurologique (2020) Vol. 176, Iss. 10, pp. 788-803
Open Access | Times Cited: 51
Jean Schoenen, Maïté Manise, Romain Nonis, et al.
Revue Neurologique (2020) Vol. 176, Iss. 10, pp. 788-803
Open Access | Times Cited: 51
Ubrogepant for the treatment of migraine
Martina Curto, Matilde Capi, Fabiola Cipolla, et al.
Expert Opinion on Pharmacotherapy (2020) Vol. 21, Iss. 7, pp. 755-759
Closed Access | Times Cited: 45
Martina Curto, Matilde Capi, Fabiola Cipolla, et al.
Expert Opinion on Pharmacotherapy (2020) Vol. 21, Iss. 7, pp. 755-759
Closed Access | Times Cited: 45
An observational study on monoclonal antibodies against calcitonin‐gene‐related peptide and its receptor
Francesca Schiano di Cola, Marco Bolchini, Giulia Ceccardi, et al.
European Journal of Neurology (2023) Vol. 30, Iss. 6, pp. 1764-1773
Open Access | Times Cited: 16
Francesca Schiano di Cola, Marco Bolchini, Giulia Ceccardi, et al.
European Journal of Neurology (2023) Vol. 30, Iss. 6, pp. 1764-1773
Open Access | Times Cited: 16
An Evidence-Based Review of Fremanezumab for the Treatment of Migraine
Ivan Urits, Gavin Clark, Daniel An, et al.
Pain and Therapy (2020) Vol. 9, Iss. 1, pp. 195-215
Open Access | Times Cited: 28
Ivan Urits, Gavin Clark, Daniel An, et al.
Pain and Therapy (2020) Vol. 9, Iss. 1, pp. 195-215
Open Access | Times Cited: 28
New Approaches to Shifting the Migraine Treatment Paradigm
Brian F. G. Johnson, Frederick G. Freitag
Frontiers in Pain Research (2022) Vol. 3
Open Access | Times Cited: 18
Brian F. G. Johnson, Frederick G. Freitag
Frontiers in Pain Research (2022) Vol. 3
Open Access | Times Cited: 18
Effectiveness and safety of eptinezumab in anti-CGRP(R) mAbs-naïve and mAbs-non responders’ patients: A retrospective observational study
Alessia Bellotti, Caterina Podella, Paola Sarchielli
Cephalalgia Reports (2025) Vol. 8
Open Access
Alessia Bellotti, Caterina Podella, Paola Sarchielli
Cephalalgia Reports (2025) Vol. 8
Open Access
Patient selection for migraine preventive treatment with anti-CGRP(r) monoclonal antibodies
Andrea Negro, Paolo Martelletti
Expert Review of Neurotherapeutics (2019) Vol. 19, Iss. 8, pp. 769-776
Closed Access | Times Cited: 27
Andrea Negro, Paolo Martelletti
Expert Review of Neurotherapeutics (2019) Vol. 19, Iss. 8, pp. 769-776
Closed Access | Times Cited: 27
CGRP en migraña: de la fisiopatología a la terapéutica
Sonia Santos Lasaosa, R. Belvís, María L. Cuadrado, et al.
Neurología (2019) Vol. 37, Iss. 5, pp. 390-402
Open Access | Times Cited: 26
Sonia Santos Lasaosa, R. Belvís, María L. Cuadrado, et al.
Neurología (2019) Vol. 37, Iss. 5, pp. 390-402
Open Access | Times Cited: 26
From spreading depolarization to epilepsy with neuroinflammation: The role of CGRP in cortex
Fátima Gimeno-Ferrer, Annett Eitner, Reinhard Bauer, et al.
Experimental Neurology (2022) Vol. 356, pp. 114152-114152
Open Access | Times Cited: 15
Fátima Gimeno-Ferrer, Annett Eitner, Reinhard Bauer, et al.
Experimental Neurology (2022) Vol. 356, pp. 114152-114152
Open Access | Times Cited: 15
The vascular role of CGRP: a systematic review of human studies
Mohammad Al‐Mahdi Al‐Karagholi, Veberka Kalatharan, Peter Schunck Fagerberg, et al.
Frontiers in Neurology (2023) Vol. 14
Open Access | Times Cited: 8
Mohammad Al‐Mahdi Al‐Karagholi, Veberka Kalatharan, Peter Schunck Fagerberg, et al.
Frontiers in Neurology (2023) Vol. 14
Open Access | Times Cited: 8
Calcitonin gene–related peptide in migraine: from pathophysiology to treatment
Sonia Santos‐Lasaosa, R. Belvís, María L. Cuadrado, et al.
Neurología (English Edition) (2021) Vol. 37, Iss. 5, pp. 390-402
Open Access | Times Cited: 17
Sonia Santos‐Lasaosa, R. Belvís, María L. Cuadrado, et al.
Neurología (English Edition) (2021) Vol. 37, Iss. 5, pp. 390-402
Open Access | Times Cited: 17
Fremanezumab for the preventive treatment of migraine in adults
Luana Lionetto, Martina Curto, Giusy Ylenia Cisale, et al.
Expert Review of Clinical Pharmacology (2019) Vol. 12, Iss. 8, pp. 741-748
Closed Access | Times Cited: 16
Luana Lionetto, Martina Curto, Giusy Ylenia Cisale, et al.
Expert Review of Clinical Pharmacology (2019) Vol. 12, Iss. 8, pp. 741-748
Closed Access | Times Cited: 16
Gαs-Coupled CGRP Receptor Signaling Axis from the Trigeminal Ganglion Neuron to Odontoblast Negatively Regulates Dentin Mineralization
Natsuki Saito, Maki Kimura, Takehito Ouchi, et al.
Biomolecules (2022) Vol. 12, Iss. 12, pp. 1747-1747
Open Access | Times Cited: 9
Natsuki Saito, Maki Kimura, Takehito Ouchi, et al.
Biomolecules (2022) Vol. 12, Iss. 12, pp. 1747-1747
Open Access | Times Cited: 9
The locus of Action of CGRPergic Monoclonal Antibodies Against Migraine: Peripheral Over Central Mechanisms
Abimael González‐Hernández, Bruno A. Marichal‐Cancino, Enrique García-Boll, et al.
CNS & Neurological Disorders - Drug Targets (2020) Vol. 19, Iss. 5, pp. 344-359
Closed Access | Times Cited: 13
Abimael González‐Hernández, Bruno A. Marichal‐Cancino, Enrique García-Boll, et al.
CNS & Neurological Disorders - Drug Targets (2020) Vol. 19, Iss. 5, pp. 344-359
Closed Access | Times Cited: 13
The Role of Anti-calcitonin Gene-related Peptide in Migraine and its Implication in Developing Countries: A Reasonable Option to Consider Despite Higher Cost
Akhtar Ali
Cureus (2019)
Open Access | Times Cited: 8
Akhtar Ali
Cureus (2019)
Open Access | Times Cited: 8
Galcanezumab for the Prevention of Migraine
Lindsay Frerichs, Deborah I. Friedman
Pain Management (2020) Vol. 11, Iss. 2, pp. 101-112
Closed Access | Times Cited: 5
Lindsay Frerichs, Deborah I. Friedman
Pain Management (2020) Vol. 11, Iss. 2, pp. 101-112
Closed Access | Times Cited: 5
The impact of CGRPergic monoclonal antibodies on prophylactic antimigraine therapy and potential adverse events
Abimael González‐Hernández, Bruno A. Marichal‐Cancino, Carlos M. Villalón
Expert Opinion on Drug Metabolism & Toxicology (2021) Vol. 17, Iss. 10, pp. 1223-1235
Closed Access | Times Cited: 4
Abimael González‐Hernández, Bruno A. Marichal‐Cancino, Carlos M. Villalón
Expert Opinion on Drug Metabolism & Toxicology (2021) Vol. 17, Iss. 10, pp. 1223-1235
Closed Access | Times Cited: 4
Eptinezumab-jjmr, a humanized monoclonal specific to Calcitonin Gene Related Peptide, for the preventive treatment of migraine in adults
Amnon A. Berger, Joseph Keefe, Cain W. Stark, et al.
Health psychology research (2022) Vol. 10, Iss. 5
Open Access | Times Cited: 2
Amnon A. Berger, Joseph Keefe, Cain W. Stark, et al.
Health psychology research (2022) Vol. 10, Iss. 5
Open Access | Times Cited: 2
Calcitonin Gene-Related Peptide Antagonists as a Savior in Episodic and Chronic Migraine: A Review
Hira Pervez, Lavina Khemani, Mahrukh A Khan, et al.
Cureus (2020)
Open Access | Times Cited: 2
Hira Pervez, Lavina Khemani, Mahrukh A Khan, et al.
Cureus (2020)
Open Access | Times Cited: 2
Fundamental and clinical neuropharmacology, a terra incognita with constantly expanding frontiers
Luc Zimmer
Fundamental and Clinical Pharmacology (2021) Vol. 35, Iss. 3, pp. 501-505
Closed Access | Times Cited: 1
Luc Zimmer
Fundamental and Clinical Pharmacology (2021) Vol. 35, Iss. 3, pp. 501-505
Closed Access | Times Cited: 1
Fremanezumab
Luana Lionetto, Matilde Capi, Valerio De Angelis, et al.
Headache (2021), pp. 131-136
Closed Access | Times Cited: 1
Luana Lionetto, Matilde Capi, Valerio De Angelis, et al.
Headache (2021), pp. 131-136
Closed Access | Times Cited: 1
Predicting CGRP-Antagonists Response Based on the Phenotypic Features of Migraine Headaches, a Retrospective Study
Zidan Awss, Rajasekaran Anindita, B Rajah Gary, et al.
International Journal of Neurology and Neurotherapy (2023) Vol. 10, Iss. 1
Open Access
Zidan Awss, Rajasekaran Anindita, B Rajah Gary, et al.
International Journal of Neurology and Neurotherapy (2023) Vol. 10, Iss. 1
Open Access
